Q1 Earnings Estimate for Verastem Issued By HC Wainwright

Verastem, Inc. (NASDAQ:VSTM) – Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Verastem in a research report issued to clients and investors on Monday, March 24th. HC Wainwright analyst S. Lee anticipates that the biopharmaceutical company will post earnings of ($0.67) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Verastem’s current full-year earnings is ($3.02) per share. HC Wainwright also issued estimates for Verastem’s Q2 2025 earnings at ($0.74) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.62) EPS, FY2026 earnings at ($1.10) EPS and FY2027 earnings at ($0.33) EPS.

VSTM has been the subject of a number of other reports. Guggenheim increased their price target on Verastem from $13.00 to $14.00 and gave the company a “buy” rating in a research note on Monday. BTIG Research increased their price objective on shares of Verastem from $13.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, December 31st. Mizuho lifted their target price on shares of Verastem from $7.00 to $9.00 and gave the stock an “outperform” rating in a research note on Thursday, December 19th. StockNews.com upgraded shares of Verastem from a “sell” rating to a “hold” rating in a research note on Monday. Finally, Royal Bank of Canada decreased their price target on shares of Verastem from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Friday, March 21st. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, Verastem has a consensus rating of “Moderate Buy” and a consensus price target of $13.88.

Verastem Stock Up 5.2 %

Verastem stock opened at $6.73 on Thursday. Verastem has a 1-year low of $2.10 and a 1-year high of $13.52. The business has a fifty day moving average price of $6.13 and a 200-day moving average price of $4.73. The company has a debt-to-equity ratio of 2.77, a current ratio of 3.23 and a quick ratio of 3.23. The stock has a market capitalization of $346.51 million, a price-to-earnings ratio of -2.11 and a beta of 0.60.

Verastem (NASDAQ:VSTM) last released its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.57).

Hedge Funds Weigh In On Verastem

Several institutional investors and hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC raised its position in Verastem by 51.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,997 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 1,698 shares in the last quarter. Invesco Ltd. grew its stake in shares of Verastem by 18.4% during the 4th quarter. Invesco Ltd. now owns 14,680 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 2,281 shares during the period. Jane Street Group LLC increased its holdings in shares of Verastem by 31.2% during the 4th quarter. Jane Street Group LLC now owns 19,932 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 4,740 shares in the last quarter. Aries Wealth Management lifted its stake in shares of Verastem by 23.3% in the 4th quarter. Aries Wealth Management now owns 26,415 shares of the biopharmaceutical company’s stock valued at $137,000 after purchasing an additional 5,000 shares during the period. Finally, Barclays PLC lifted its stake in shares of Verastem by 10.3% in the 4th quarter. Barclays PLC now owns 61,445 shares of the biopharmaceutical company’s stock valued at $318,000 after purchasing an additional 5,737 shares during the period. Institutional investors and hedge funds own 88.37% of the company’s stock.

Insiders Place Their Bets

In other Verastem news, CEO Dan Paterson sold 8,568 shares of the stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $5.24, for a total transaction of $44,896.32. Following the sale, the chief executive officer now directly owns 347,581 shares of the company’s stock, valued at approximately $1,821,324.44. This trade represents a 2.41 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders sold 9,960 shares of company stock valued at $53,498. 2.20% of the stock is owned by insiders.

Verastem Company Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.